Last reviewed · How we verify
DTP-IPV
DTP-IPV, marketed by Merck Sharp & Dohme LLC, is a small molecule with a key composition patent expiring in 2028. The drug's mechanism involves interacting with a specific target in the body to produce a therapeutic effect, positioning it as a unique offering in its class. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | DTP-IPV |
|---|---|
| Also known as | Tetrabik™, BIKEN |
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine (PHASE3)
- Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants (NA)
- National Vaccine Adverse Event Reporting Survey and Etiology
- Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR (PHASE4)
- Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants (PHASE4)
- A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults (PHASE1)
- Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060) (PHASE4)
- Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DTP-IPV CI brief — competitive landscape report
- DTP-IPV updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI